164 related articles for article (PubMed ID: 33811135)
1. Characterisation of protein-truncating and missense variants in
Ng PS; Boonen RA; Wijaya E; Chong CE; Sharma M; Knaup S; Mariapun S; Ho WK; Lim J; Yoon SY; Mohd Taib NA; See MH; Li J; Lim SH; Tan EY; Tan BK; Tan SM; Tan VK; van Dam RM; Rahmat K; Yip CH; Carvalho S; Luccarini C; Baynes C; Dunning AM; Antoniou A; van Attikum H; Easton DF; Hartman M; Teo SH
J Med Genet; 2022 May; 59(5):481-491. PubMed ID: 33811135
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore.
Phuah SY; Lee SY; Kang P; Kang IN; Yoon SY; Thong MK; Hartman M; Sng JH; Yip CH; Taib NA; Teo SH
PLoS One; 2013; 8(8):e73638. PubMed ID: 23977390
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.
Janssen B; Bellis S; Koller T; Tischkowitz M; Liau SS
J Hum Genet; 2020 Jan; 65(2):199-205. PubMed ID: 31619740
[TBL] [Abstract][Full Text] [Related]
6. Rare germline mutations in PALB2 and breast cancer risk: a population-based study.
Tischkowitz M; Capanu M; Sabbaghian N; Li L; Liang X; Vallée MP; Tavtigian SV; Concannon P; Foulkes WD; Bernstein L; ; Bernstein JL; Begg CB
Hum Mutat; 2012 Apr; 33(4):674-80. PubMed ID: 22241545
[TBL] [Abstract][Full Text] [Related]
7. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of 84 PALB2 variants of uncertain significance.
Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
[TBL] [Abstract][Full Text] [Related]
9. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
[TBL] [Abstract][Full Text] [Related]
11. A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.
Brnich SE; Arteaga EC; Wang Y; Tan X; Berg JS
J Mol Diagn; 2021 Jul; 23(7):847-864. PubMed ID: 33964450
[TBL] [Abstract][Full Text] [Related]
12. Evolutionary Origin of Human
Chian JS; Li J; Wang SM
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511102
[No Abstract] [Full Text] [Related]
13. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
[TBL] [Abstract][Full Text] [Related]
14. Rare, protein-truncating variants in
Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
16. Novel germline PALB2 truncating mutations in African American breast cancer patients.
Zheng Y; Zhang J; Niu Q; Huo D; Olopade OI
Cancer; 2012 Mar; 118(5):1362-70. PubMed ID: 21932393
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
[TBL] [Abstract][Full Text] [Related]
18. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
[TBL] [Abstract][Full Text] [Related]
19. Rare germline variants in PALB2 and BRCA2 in familial and sporadic chordoma.
Xia B; Biswas K; Foo TK; Gomes TT; Riedel-Topper M; Southon E; Kang Z; Huo Y; Reid S; Stauffer S; Zhou W; Zhu B; Koka H; Yepes S; Brodie SA; Jones K; Vogt A; Zhu B; Carter B; Freedman ND; Hicks B; Yeager M; Chanock SJ; Couch F; Parry DM; Monteiro AN; Goldstein AM; Carvalho MA; Sharan SK; Yang XR
Hum Mutat; 2022 Oct; 43(10):1396-1407. PubMed ID: 35762214
[TBL] [Abstract][Full Text] [Related]
20. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
